Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anita Howe

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|November 16, 2011
Quantitation of amyloid beta peptides in CSF by surface enhanced MALDI-TOFEddie Takahashi, Anita Howe, Ole Vesterqvist, et al.
Antimicrobial Agents and Chemotherapy|April 19, 2017
Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 RepliconsErnest Asante-Appiah, Stephanie Curry, Patricia McMonagle, et al.
Hepatology (Baltimore, Md.)|April 27, 2016
ReplyVeronica Miller, Patrick Harrington, Anita Howe, et al.
Hepatology (Baltimore, Md.)|June 23, 2015
Hepatitis C virus drug resistance-associated substitutions: State of the art summaryErik Lontok, Patrick Harrington, Anita Howe, et al.
Journal of Hepatology|June 17, 2017
Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimerasSimone Susser, Julia Dietz, Bernhard Schlevogt, et al.
Hepatology (Baltimore, Md.)|October 23, 2016
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trialEric Lawitz, Fred Poordad, Julio A Gutierrez, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|November 16, 2011
Quantitation of amyloid beta peptides in CSF by surface enhanced MALDI-TOFEddie Takahashi, Anita Howe, Ole Vesterqvist, et al.
Antimicrobial Agents and Chemotherapy|April 19, 2017
Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 RepliconsErnest Asante-Appiah, Stephanie Curry, Patricia McMonagle, et al.
Hepatology (Baltimore, Md.)|April 27, 2016
ReplyVeronica Miller, Patrick Harrington, Anita Howe, et al.
Hepatology (Baltimore, Md.)|June 23, 2015
Hepatitis C virus drug resistance-associated substitutions: State of the art summaryErik Lontok, Patrick Harrington, Anita Howe, et al.
Journal of Hepatology|June 17, 2017
Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimerasSimone Susser, Julia Dietz, Bernhard Schlevogt, et al.
Hepatology (Baltimore, Md.)|October 23, 2016
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trialEric Lawitz, Fred Poordad, Julio A Gutierrez, et al.
Pageof 1